Radiance V2
Gmv Soluciones Globales Internet S.A.U.
FDA Clearance Information
Radiance v2 was cleared by the FDA through the 510k pathway on January 31, 2014. It is manufactured by Gmv Soluciones Globales Internet S.A.U. and classified as a Class 2 device under product code MUJ.
What It Is
FDA-Cleared Indications
- Use in establishing or maintaining vascular access for hemodialysis, consistent with the FDA product classification for dialysis-access devices.
Clinical Applications
- Supporting vascular access used to connect a patient’s bloodstream with a hemodialysis circuit.
- Use during hemodialysis treatment when repeated access to the bloodstream is required.
- Management of dialysis-related vascular access in patients receiving renal replacement therapy.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- The available record does not specify device dimensions, access configuration, flow characteristics, or compatibility with particular dialysis systems; clinicians should consult the current manufacturer labeling.
- Use requires appropriate vascular-access assessment and sterile technique.
- The record does not state MRI safety or conditional-use requirements. MRI compatibility should be confirmed in the device labeling before scanning.
- Potential complications depend on the access procedure and may include bleeding, infection, thrombosis, stenosis, malfunction, or vascular injury.
- Contraindications, dwell time, replacement intervals, and handling requirements should be determined from the current instructions for use.
Frequently Asked Questions
What are the clinical indications for Radiance v2?
Radiance v2 is indicated for use in dialysis access, facilitating vascular access for patients undergoing dialysis treatment.
What outcomes have been reported in clinical studies?
No specific outcomes have been reported in the provided studies, as they focus on technical aspects rather than clinical efficacy.
What complications have been reported?
No specific complications have been reported in the provided studies, as they do not focus on safety data.